The NCI60 human tumour cell line anticancer drug screen by Shoemaker Robert H in Nature reviews. Cancer (2006). PubMed


The US National Cancer Institute (NCI) 60 human tumour cell line anticancer drug screen (NCI60) was developed in the late 1980s as an in vitro drug-discovery tool intended to supplant the use of transplantable animal tumours in anticancer drug screening. This screening model was rapidly recognized as a rich source of information about the mechanisms of growth inhibition and tumour-cell kill. Recently, its role has changed to that of a service screen supporting the cancer research community. Here I review the development, use and productivity of the screen, highlighting several outcomes that have contributed to advances in cancer chemotherapy.

[ hide abstract ]

Discussed In Paper


Dosing Information

No dosing information annotated.